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Abstract
Objective—Parkinson’s disease (PD) has long been conceptualized as a motor disorder, but non-
motor symptoms also manifest in the disease and significantly reduce quality of life. Anxiety and 
cognitive dysfunction are prevalent non-motor symptoms, even in early disease stages, but the 
relation between these symptoms remains poorly understood. We examined self-reported anxiety 
and neurocognitive function, indexed by measures of executive function (set-shifting and 
phonemic fluency), categorical fluency, and attention/working memory. We hypothesized that 
anxiety would correlate with cognitive performance.
Method—The Beck Anxiety Inventory and cognitive tests (Trail Making, Verbal Fluency, Digit 
Span) were administered to 77 non-demented adults with mild to moderate idiopathic PD (39 men, 
38 women; mean age = 62.9 years).
Results—Higher anxiety was associated with more advanced disease stage and severity and with 
poorer set-shifting, when using a derived metric to account for motoric slowing. Depression 
correlated with greater anxiety and disease severity, but not with cognitive performance.
Conclusions—Our findings support the association of anxiety with a specific domain of 
executive function, set-shifting, in non-demented individuals with mild to moderate PD, raising the 
possibility that treatment of anxiety may alleviate aspects of executive dysfunction in this 
population.
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Afflicting approximately 1% of the population over age 60 (Mayeux, 2003; Prediger, 
Matheus, Schwarzbold, Lima, & Vital, 2012), Parkinson’s disease (PD) is associated with 
classic motor symptoms as well as with a variety of non-motor symptoms, including 
cognitive dysfunction and neuropsychiatric symptoms (Cronin-Golomb, 2013). Non-motor 
symptoms are often comorbid with one another, with increased comorbidity associated with 
greater disease severity as indexed by motor and functional measures (Shulman, Taback, 
Bean, & Weiner, 2001). These non-motor symptoms significantly contribute to a poor 
quality of life in individuals with PD (Duncan et al., 2014), often to a greater extent than the 
motor symptoms (Bonnet & Czernecki, 2013; Qin et al., 2009), but they remain 
understudied and under-diagnosed (Shulman, Taback, Rabinstein, & Weiner, 2002). In 
particular among the non-motor symptoms, anxiety and cognitive dysfunction are highly 
prevalent in PD, even in the early stages of the disease. Emerging research is beginning to 
more closely consider cognitive impairment and affective disorders in this population 
(Bogdanova & Cronin-Golomb, 2012, 2013; Pluck & Brown, 2002; Santangelo et al., 2009), 
but the literature remains limited (Poletti, De Rosa, & Bonuccelli, 2012).
Although the relation between anxiety and cognitive function is not well characterized in 
PD, anxiety has long been associated with impaired cognitive performance in non-PD 
populations, particularly on attentionally demanding tasks (Derakshan & Eysenck, 2009). In 
older adults, including those with mild cognitive impairment, anxiety has been associated 
with cognitive deficits (Forsell, Palmer, & Fratiglioni, 2003) and has also been shown to 
predict cognitive decline in individuals without depression or cognitive impairment (Sinoff 
& Werner, 2003). There is some evidence that those who develop anxiety disorders later in 
life (age 55 and above; an age group that includes most individuals with PD) may exhibit 
poorer overall cognition than those with early-onset anxiety disorders (DeLuca et al., 2005), 
suggesting that anxious individuals with PD may be at an increased risk for cognitive 
dysfunction due to their age alone. Specifically, individuals with anxiety disorders exhibited 
impairments in executive function and episodic memory (Airaksinen, Larsson, & Forsell, 
2005), and older adults with generalized anxiety disorder showed impairments in short-term 
and working memory, information processing speed, inhibition and problem-solving, and 
immediate and delayed memory, compared to control adults (Butters et al., 2011; Caudle et 
al., 2007; Mantella et al., 2007). These findings suggest that anxiety and cognition are likely 
to also be related in PD.
The lack of research on affective symptoms in PD is concerning, as clinically significant 
anxiety occurs in up to 40% of individuals with PD (Aarsland, Marsh, & Schrag, 2009; 
Walsh & Bennett, 2001), and anxiety disorders occur at higher rates in PD than in the overall 
population (Nuti et al., 2004; Walsh & Bennett, 2001). Anxiety in PD contributes to reduced 
subjective quality of life (Carod-Artal, Ziomkowski, Mourao Mesquita, & Martinez-Martin, 
2008; Dissanayaka et al., 2010; Hanna & Cronin-Golomb, 2012; Havlikova et al., 2011; 
Leentjens, Dujardin, Marsh, Martinez-Martin, et al., 2011; McKinlay et al., 2008; Pontone et 
al., 2009) and greater self-perceived disability (Witjas et al., 2002). Of further concern in 
PD, anxiety may compromise information processing ability and thereby negatively affect 
gait, potentially leading to falls (Ehgoetz Martens, Ellard, & Almeida, 2015). Anxiety can 
also co-occur with depression in PD (Dissanayaka et al., 2010; Menza, Robertson-Hoffman, 
& Bonapace, 1993), and clinically significant depressive symptoms occur at rates of 35% in 
Reynolds et al. Page 2
Neuropsychology. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
this population (Reijnders, Ehrt, Weber, Aarsland, & Leentjens, 2008). Consideration of 
comorbid depression is important, given that depression in PD has been associated with 
cognitive decline (Starkstein, Mayberg, Leiguarda, Preziosi, & Robinson, 1992), and with 
executive dysfunction and working memory deficits, even in early disease stages (Dirnberger 
& Jahanshahi, 2013; Uekermann et al., 2003).
Cognitive dysfunction occurs in the majority of individuals with PD (Mamikonyan et al., 
2009). Up to 57% of those with PD are affected by mild cognitive impairment within the 
first 3–5 years after diagnosis (Williams-Gray, Foltynie, Brayne, Robbins, & Barker, 2007), 
and up to 14% of individuals with PD over age 65 develop some type of cognitive 
impairment each year (Galvin, 2006). Cognitive deficits in PD are associated with greater 
motor severity and typically include executive dysfunction, visuospatial and constructional 
deficits, and attention/working memory deficits (Dirnberger & Jahanshahi, 2013; 
Muslimovic, Post, Speelman, & Schmand, 2005; Pfeiffer, Lokkegaard, Zoetmulder, Friberg, 
& Werdelin, 2014). Visuospatial, attentional, and executive deficits are the most typical in 
PD individuals with mild cognitive impairment (PD-MCI) (Aarsland, Bronnick, & Fladby, 
2011). In a recent study of individuals with mild to moderate PD with neither dementia nor 
mild cognitive impairment, measures of attention and executive function (frontal-type tests) 
were the most sensitive to cognitive compromise (Miller, Neargarder, Risi, & Cronin-
Golomb, 2013). Understanding cognitive deficits in the early stages of the disease is 
important because they may predict the progression of cognitive dysfunction to dementia 
(Azuma, Cruz, Bayles, Tomoeda, & Montgomery, 2003; Kehagia, Barker, & Robbins, 2010; 
Levy et al., 2002; Williams-Gray et al., 2009; Williams-Gray et al., 2007).
Regarding potential mechanisms, similar brain regions and neurotransmitter systems have 
been implicated in the development of anxiety and cognitive dysfunction in PD and in the 
overall population, suggesting that the symptoms may be related in PD, at least in part, as a 
result of shared underlying neurocircuitry. First, disrupted frontostriatal circuitry likely 
contributes to the executive deficits in non-demented individuals with PD, including deficits 
in flexibility, planning, and working memory (Kehagia, Barker, et al., 2010). Specifically, 
these impairments have been associated with prefrontal dopaminergic dysregulation (Cools, 
Barker, Sahakian, & Robbins, 2001; Narayanan, Rodnitzky, & Uc, 2013) and basal ganglia 
dysfunction (Kehagia, Barker, et al., 2010; Obeso, Rodriguez-Oroz, Rodriguez, Arbizu, & 
Gimenez-Amaya, 2002; Obeso et al., 2000). At the same time, widespread Lewy-body 
pathology occurs in PD in brain areas associated with anxiety, such as the amygdala, which 
has major projections to the prefrontal cortex (Braak et al., 1994; Braak, Ghebremedhin, 
Rub, Bratzke, & Del Tredici, 2004; Pontone et al., 2009; Prediger et al., 2012), suggesting 
potential disruption to affective and cognitive functioning. Emerging work also points to a 
potential role of dopaminergic degeneration in the ventral tegmental area in the 
pathophysiology of non-motor symptoms in PD, namely depression, anxiety, and executive 
dysfunction (Alberico, Cassell, & Narayanan, 2015).
The sources of mild cognitive deficits in early-stage PD may also include structural changes 
in frontal and temporoparietal regions as well as non-dopaminergic dysfunction (Hanna-
Pladdy, Jones, Cabanban, Pahwa, & Lyons, 2013). Noradrenaline and serotonin have been 
implicated in the development of anxiety in PD and the general population (Millan, 2003; 
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Prediger et al., 2012; Ressler & Nemeroff, 2000). Specifically, noradrenergic dysfunction 
has been implicated in deficits in attentional set-shifting, such as the task-switching deficits 
observed in individuals with PD (Kehagia, Cools, Barker, & Robbins, 2009; Kehagia, 
Murray, & Robbins, 2010). In PD, noradrenergic dysfunction has been associated with 
depression and anxiety (Remy, Doder, Lees, Turjanski, & Brooks, 2005), and also with 
cognitive impairment and dementia (Del Tredici & Braak, 2013). Likewise, serotonergic 
dysfunction occurs early in PD and may contribute to anxiety, considering the projections 
from the serotonergic raphe nuclei to corticolimbic regions (Prediger et al., 2012). 
Serotonergic neuronal loss has the potential to compromise cognition as well (Halliday, 
Leverenz, Schneider, & Adler, 2014), based on reduced levels of serotonin observed in PD 
in key brain regions, such as the hippocampus and frontal cortex (Scatton, Javoy-Agid, 
Rouquier, Dubois, & Agid, 1983).
To date, the limited research on affective symptoms and cognitive function in PD has 
investigated the effects of depression and apathy on cognition, with relatively minimal 
attention given to the study of anxiety and cognition in this population (Poletti et al., 2012). 
In the present study, we sought to expand our understanding of this relation in a relatively 
large sample of individuals with PD. We focused on executive functioning (set-shifting, 
phonemic fluency) and attention/working memory, as deficits in these domains are usually 
the cognitive symptoms that are documented in mild to moderate PD (Miller et al., 2013). 
The main hypothesis was that higher anxiety levels would correlate with poorer performance 
on neuropsychological measures of executive function and attention.
Method
Participants
Participants included 77 non-demented individuals with PD (39 men, 38 women; mean age 
= 62.9 years, SD 7.4), who were referred from the Parkinson’s Disease Center of Boston 
Medical Center and local PD support groups. These individuals were participants in studies 
that used partly overlapping measures of cognition, as well as the same measures of anxiety. 
The study protocols were approved by the Boston University Institutional Review Board, 
with consent obtained according to the Declaration of Helsinki.
Participants with PD met the clinical criteria for mild to moderate idiopathic disease, 
following the United Kingdom Parkinson’s Disease Society Brain Bank diagnostic criteria 
(Hughes, Daniel, Kilford, & Lees, 1992). Exclusion criteria included coexisting serious 
chronic illness (including psychiatric or neurological); use of psychoactive medications 
besides antidepressants and anxiolytics, which are commonly prescribed in PD; history of 
intracranial surgery, traumatic brain injury, alcoholism or other drug abuse; and visual acuity 
poorer than 20/40. All participants were non-demented, as indicated by scores of 25 or better 
on a standard cognitive screening measure, the Mini-Mental State Examination (MMSE) 
(Folstein, Folstein, & McHugh, 1975), and performance on the several cognitive tests 
described below.
Motor disability was staged using the Hoehn & Yahr scale (Hoehn & Yahr, 1967). There 
were 15 participants in Stage I (unilateral), 51 in Stage II (mild bilateral), and 11 in Stage III 
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(moderate bilateral). Of the 77 participants, 40 had motor symptom onset on the left body 
side (LPD), 36 on the right side (RPD), and one had bilateral onset. All were tested in their 
“on” medication state. Disease and motor disability was rated with the Unified Parkinson’s 
Disease Rating Scale (UPDRS: (Fahn & Elton, 1987)). UPDRS scores were available for 
45/77 participants. UPDRS total score (sections 1–3) was used as a measure of overall 
disease severity, and the motor subscale (section 3) was used as a measure of motor 
symptom severity. Levodopa equivalent dosages (LED) were calculated using a standard 
formula (Tomlinson et al., 2010); medication information was available for 39/77 
participants. Of these 39 participants, five were taking anti-anxiety medication, and three 
were taking antidepressant medication. Table 1 provides a summary of participant 
characteristics.
Procedure and Measures
Following the administration of the MMSE, participants completed a series of 
neuropsychological tests and mood questionnaires. The neuropsychological tests assessed 
current cognitive functioning primarily in the domains of executive functioning, working 
memory, and attention because these were the tests for which we had been collecting data 
across studies for several years, which permitted us to examine a large sample. Not all 
participants received all tests.
Tests of attention and working memory included the Trail Making Test A, and Digit Span 
Forward and Backward. Tests of executive functioning included the Trail Making Test B and 
Phonemic Fluency; Category Fluency was also administered.
We administered the Digit Span subtest from the Wechsler Memory Scale III (Wechsler, 
1997) to assess attention (Forward and Backward conditions) and working memory 
(Backward condition). Score for each condition was the total number of correct trials. The 
Trail-Making Test (TMT) (Tombaugh, 2004) was given to evaluate attention, set-shifting, 
and executive function. The task was to quickly draw lines connecting numbers in order 
(TMT-A; attention), and alternate between numbers and letters in order (TMT-B; set-
shifting, executive function). Score for each was time to completion. To isolate set-shifting 
measured by TMT-B, a derived TMT-difference score was calculated (TMT-B – TMT-A), 
which removes the psychomotor component of the task that is captured in TMT-A 
(O’Rourke et al., 2011). To further assess executive function, participants engaged in the 
Word Association Test for phonemic fluency (Delis, Kaplan, & Kramer, 2001). They were 
instructed to name as many unique words beginning with the letters F, A, and S (phonemic 
fluency; FAS) as possible. The categorical fluency trial was also administered, which 
required participants to name as many unique animals (categorical fluency; Animals) as 
possible. The time limit for each trial was 60 seconds. Score for phonemic fluency was the 
total number of correct responses, summed across the F, A, and S trials. Score for 
categorical fluency was the total number of correct responses.
To measure anxiety symptoms, participants were administered the Beck Anxiety Inventory 
(BAI) (Beck & Steer, 1993). The BAI is a 21-item self-report measure of anxiety, on which 
higher scores indicate more anxiety symptoms. Participants also were given the Beck 
Depression Inventory II (BDI) (Beck, Steer, & Brown, 1996) to assess current depressive 
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symptoms. The BDI is a 21-item self-report measure of depressive symptoms, with higher 
scores indicative of higher levels of depression.
Data Analysis
Statistical analyses were conducted with IBM SPSS Statistics, Version 23. Correlational 
analyses were conducted to determine whether neurocognitive functions were related to 
symptoms of anxiety in the PD sample. The relation between anxiety and cognitive 
performance was examined using correlational analyses. The skew in the BAI score 
distribution dictated the use of non-parametric analyses (Spearman’s correlations). The 
sample size for each analysis was dependent upon the number of individuals in the sample 
who had been administered those particular cognitive tests. For the 77 PD participants, the 
sample size for each analysis ranged from 57 to 62. By test, the sample sizes were as 
follows: TMT-A: 62; TMT-B: 62; FAS: 59; Animals: 57; Digit Span Forward: 58; Digit 
Span Backward: 58. To account for the number of analyses and correlations between 
outcome variables, we used a conservative alpha level of .01 because some of the tests 
belonged to the same cognitive domain. Because some participants did complete all of the 
cognitive tests, a conservative alpha level was used to minimize Type I error rate.
Results
Within-Group Levels of Anxiety and Depression
The mean BAI in the sample was 10.0 (SD 7.7). Twelve of the 77 PD participants reported 
clinically significant levels of anxiety on the BAI when using a highly specific cutoff score 
of 18 (Higginson, Fields, & Troster, 2001). Four of the 12 had clinically significant 
depression scores (BDI-II ≥17). In this subgroup of 12, mean BDI-II was 15.2 (SD 7.9), 
mean age was 65.8 years (SD 9.8), mean education was 14.4 years (SD 2.4), mean disease 
duration was 10.9 years (SD 8.4), and all were in H&Y stages 2 or 3. Of these 12 with 
clinically significant anxiety, nine completed TMT-A and TMT-B, and seven completed 
Verbal Fluency (FAS and Animals) and Digit Span.
The mean BDI-II in the sample was 8.2 (SD 6.2). Clinically significant levels of depression 
were reported by eight of the participants on the BDI-II, using a highly specific cutoff score 
of 17 (Higginson et al., 2001). Four of the eight had clinically significant anxiety scores 
(BAI ≥18).
Within the PD group, levels of anxiety did not differ for men vs. women (t(75) = .09, p=.93) 
or by side of motor symptom onset (LPD, RPD; t(74) = 1.07, p=.29). Depression levels did 
not differ between men and women with PD (t(75) = 1.71, p=.09) or by side of motor 
symptom onset (LPD, RPD; t(74) = .03, p=.98). Age at testing did not correlate with anxiety 
(ρ=−.14, p=.23). Data were accordingly collapsed across gender, side of motor symptom 
onset, and age for the following analyses.
Within-Group Correlational Analyses
Anxiety correlated with certain clinical characteristics, as shown in Table 2. These included 
disease stage (H&Y), disease severity (UPDRS total), and depression, with higher anxiety 
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associated with more advanced stage, greater severity, and higher depression. Anxiety also 
correlated with education and disease duration at a trend level, with higher anxiety 
associated with lower education and longer disease duration. Anxiety was not associated 
with medication usage (LED) or motor symptom severity. Depression correlated with 
disease severity (ρ =.47, p=.001) and there was a trend for a correlation with motor symptom 
severity (ρ=.32, p=.03), but not with age, education, disease duration, medication usage, or 
disease stage (all ps>.05; see Table 3).
Because demographic and mood variables may influence neuropsychological performance, 
we conducted correlational analyses to examine these potential effects in our PD sample. 
Age, education, medication usage (LED), motor symptom severity, and overall disease 
severity (UPDRS total) did not correlate with cognitive performance (all ρs≤ |.26|, ps≥.04); 
UPDRS and LED correlational analyses were conducted with the subset of participants for 
whom those data were available. Disease stage (H&Y) correlated with performance on 
TMT-B (ρ=.37, p=.003), and there were trends for TMT B-A (ρ=.29, p=.02) and category 
fluency (ρ=−.31, p=.02), but not for other cognitive tests (all ρs≤ |.22|, ps ≥.087). There were 
trends for disease duration to correlate with TMT-B (ρ=.29, p=.02) and TMT B-A (ρ=.30, 
p=.02), but not for other cognitive tests (all ρs< |.20|, ps ≥.15).
Anxiety significantly correlated with performance on TMT-B (ρ=.37, p=.003; Figure 1), and 
remained significant after removing the psychomotor component of the task (TMT B-A: ρ=.
34, p=.007; Table 4). Anxiety did not correlate with performance on the tests of phonemic 
fluency, categorical fluency, attention, or working memory (Table 4). Depression did not 
correlate with performance on any of the cognitive measures (Table 5). The pattern of 
findings remained the same after excluding the eight participants with clinically significant 
depression scores, such that there was a trend for anxiety to correlate with TMT-B (ρ=.32, 
p=.016) and TMT B-A (ρ=.33, p=.016), but not with other cognitive measures (all ρs≤ |.23|, 
ps ≥.11).
Discussion
We examined the relation between anxiety and cognitive functioning in a large, well-
characterized sample of non-demented individuals with mild to moderate idiopathic PD. 
Higher anxiety was significantly associated with more advanced disease stage and severity, 
and there was a trend for anxiety to also be associated with lower education and longer 
disease duration. Anxiety also correlated with depression, and depression was associated 
with greater disease severity, with a trend for an association with motor symptoms as 
indexed by the UPDRS motor subscale. Regarding cognitive function, higher anxiety 
correlated with poorer set-shifting (TMT-B) among PD participants even after removing the 
psychomotor component of the cognitive task (TMT B-A). Anxiety level did not correlate 
with performance on tests of attention, working memory, phonemic fluency, or categorical 
fluency. Depression did not correlate with cognitive performance, which is likely related to 
floor effects as the mean depression score in our sample was well within normal limits.
We had originally predicted an association between anxiety and executive and attentional 
dysfunction in PD. Our results are consistent with a recent study by Martens and colleagues 
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(2016) that reported a correlation between anxiety and TMT B-A in PD, but no significant 
correlations between anxiety and the digit span subtests. Our findings with a relatively large 
number of measures of executive function and attention (including digit span) accord with 
and expand upon those of the study of Martens and colleagues, highlighting the specific 
association between anxiety and set-shifting in mild to moderate PD. The relation between 
anxiety and TMT-B is consistent with attentional control theory (Eysenck, Derakshan, 
Santos, & Calvo, 2007), which asserts that anxiety decreases attentional control and 
increases attention to threat, thereby compromising cognitive processes including inhibition 
and shifting. Consistent with this theory, in a sample of community-dwelling older adults, 
individuals with increased anxiety showed poorer processing speed/shifting attention and 
inhibition abilities (Beaudreau & O’Hara, 2009), which is in keeping with the association we 
observed between anxiety and set-shifting in our PD sample.
An earlier paper from our lab examined anxiety and cognition as related to side of motor 
symptom onset in PD (Bogdanova & Cronin-Golomb, 2012). A consistent finding was the 
relation between disease duration and anxiety, which was observed in the 2012 sample and 
at a trend level in the present sample, suggesting that the relation between anxiety and 
cognition may evolve as the disease progresses. The current study, relative to the 2012 study, 
included a larger sample of individuals with mostly mild anxiety in early disease stages, 
with analyses collapsed across side of motor symptom onset. We also included discussion of 
depression and motor symptoms when possible and used a derived metric to better isolate 
set-shifting and account for motor slowing. Of note, the present sample was similar to the 
2012 sample in age and gender distribution, but current participants were milder overall, as 
indexed by shorter disease duration (6.5 years compared to 8.7) and less advanced disease 
stage (H&Y stages 1–3 compared to stages 2–3), which underscores the importance of 
studying anxiety and cognition even in the early stages of PD.
It is important to note that neuropsychological tests vary in their sensitivity to cognitive 
impairment in PD (Miller et al., 2013); hence, it is possible that some of our cognitive 
measures were not sensitive enough to capture the relation between anxiety and mild 
cognitive deficits in our sample of high-functioning, non-demented PD participants with 
mostly quite mild anxiety symptoms. In a sample of 42 non-demented PD participants and 
28 control participants, 36% of the PD group showed deficits (defined at 1.5 SD below the 
control-group mean) on TMT-B, while only 15% showed deficits on Digit Span Forward and 
Digit Span Backward, suggesting that TMT-B performance may be affected to a greater 
extent than Digit Span in early PD (Miller et al., 2013). Anxiety may impair cognitive 
performance, especially on complex or attentionally demanding tasks (Derakshan & 
Eysenck, 2009), which may explain the observed association between anxiety and TMT-B, 
and the lack of association between anxiety and a relatively simple task (Digit Span 
Forward) in our sample. Although Digit Span Backward is also a demanding task, there was 
greater variability in our sample on TMT-B (SD=45.8) than Digit Span Backward (SD=2.8), 
which may have reduced the power to discern an association between anxiety and working 
memory. Likewise, although phonemic fluency is often impaired in early PD (Miller et al., 
2013), in our present sample there was considerably less variability in performance of this 
test (SD=11.5) than for TMT-B. Also, the reduced power of non-parametric analyses, the use 
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of which was dictated by the data characteristics, may have limited our ability to detect 
significant correlations between anxiety and measures of fluency or attention.
Our study was subject to limitations. First, our cognitive assessment was restricted to tests of 
executive function, attention, and categorical fluency. We drew upon neuropsychological 
data from several years of consecutive participants, and these were the tests that were 
common across that time period. The advantage of the selection of the tests was the large 
sample size for whom anxiety and cognition in a particular domain could be examined. 
Future research on anxiety and cognition in PD should include a more comprehensive 
assessment of cognitive function, and in particular, measures of complex visuospatial 
function and reasoning, as deficits in these domains are regularly observed in PD (Amick, 
Miller, Neargarder, & Cronin-Golomb, 2012; Amick, Schendan, Ganis, & Cronin-Golomb, 
2006; Bogdanova & Cronin-Golomb, 2012). Second, our sample was assessed with only one 
measure of anxiety, the BAI, which includes several somatically-based items, e.g. 
“wobbliness in legs,” “unsteady,” “hands trembling,” “shaky,” which are similar to PD 
motor symptoms (e.g., tremor or feelings of unsteadiness) (Leentjens et al., 2008; Leentjens, 
Dujardin, Marsh, Richard, et al., 2011). Mitigating this concern, we have found no 
difference in the ability of the BAI and its less somatically-laden counterpart, the State-Trait 
Anxiety Inventory, to predict quality of life in mild to moderate PD (Hanna & Cronin-
Golomb, 2012). Future studies may consider inclusion of recently developed PD-specific 
anxiety scales, such as the Parkinson Anxiety Scale (Leentjens et al., 2014). Third, our 
sample consisted of non-demented and mainly high-functioning individuals with PD who 
reported mostly mild to moderate levels of anxiety. The relation may be different in 
individuals with more advanced PD or more severe anxiety. Inclusion of a PD control group 
(e.g., non-anxious vs. highly anxious PD participants), may elucidate the effects of anxiety 
on cognition when controlling for the cognitive dysfunction associated with the disease itself 
(e.g. executive deficits due to frontostriatal disruption). Finally, information about disease 
severity (UPDRS) was available for the majority, though not all, of our participants with PD 
(45/77), which limits our interpretation of the relation between anxiety, cognition, and motor 
symptom severity. Among the subset with UPDRS scores, motor symptom severity did not 
correlate with anxiety or cognition, nor was there a relation between anxiety and cognition, 
likely due to floor effects, as the BAI mean was quite low (6.6). We included the participants 
without UPDRS data in order to increase the range of BAI scores and examine the relation 
between anxiety and cognition in a larger PD sample.
Taken together, our results suggest that anxiety may be related to poorer performance on 
measures of set-shifting even in high-functioning individuals with mild to moderate PD. 
With a better understanding of the manifestation of non-motor symptoms in PD subgroups, 
we can hope to increase recognition of anxiety and cognitive dysfunction, particularly in the 
early stages of the disease, in order to inform subsequent treatment options. This is 
important because, as we have documented, anxiety may deleteriously affect quality of life 
to a greater extent than do the motor symptoms of PD (Hanna & Cronin-Golomb, 2012). 
With research dedicated to a more comprehensive and systematic evaluation of anxiety and 
cognition in PD at various stages of the disease, we can work toward developing treatment 
approaches to address the often devastating effects of mood and cognitive impairments in 
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PD, and ultimately improve daily functioning and quality of life for people living with this 
disorder.
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Figure 1. 
The line demonstrates a significant correlation between BAI and TMT-B among PD 
participants (ρ=.37, p=.003). PD = all Parkinson’s disease participants; BAI=Beck Anxiety 
Inventory; TMT-B=Trail Making Test B.
Reynolds et al. Page 15
Neuropsychology. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Reynolds et al. Page 16
Table 1
Demographic, Clinical, and Neuropsychological Characteristics. Means (M) and Standard Deviations (SD), 
Unless Otherwise Noted
Age 62.9 (7.4)
Men:Women 39:38
Education 17.1 (2.6)
MMSEa 28.8 (1.2)
Disease Duration 6.5 (5.4)
H&Yb 2 (1–3)
UPDRS Totalc 27.0 (10.7)
UPDRS Motor Subscaled 16.4 (7.3)
LEDe 361 (231)
BAI 10.0 (7.7)
BDI-II 8.2 (6.2)
TMT-A (sec) 33.6 (15.0)
TMT-B (sec) 79.0 (45.8)
TMT B–A (sec) 45.4 (38.2)
FAS (total) 43.9 (11.5)
Animals (total) 22.4 (5.9)
Digit Span Forward (total) 11.1 (2.6)
Digit Span Backward (total) 7.5 (2.8)
a
Mini-Mental State Examination
b
Hoehn & Yahr stage: Median (range)
cUnified Parkinson’s Disease Rating Scale (UPDRS) Total (sections 1–3); UPDRS scores were available for 45/77 participants.
dUnified Parkinson’s Disease Rating Scale (UPDRS) Motor Subscale (section 3).
e
Levodopa-equivalent dosages (LED); medication information was available for 39/77 participants.
BAI=Beck Anxiety Inventory; BDI-II=Beck Depression Inventory-II; TMT-A=Trail Making Test A; TMT-B=Trail Making Test B; FAS=phonemic 
fluency; Animals=categorical fluency.
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Table 2
Spearman’s Correlations between Anxiety (BAI) and Participant- and Disease-related Variables in PD
VARIABLE rho p-value N
Age −.14 .23 77
Education −.28 .016 77
Disease Duration .29 .01 77
H&Y .31** .007 77
UPDRS total .41** .005 45
UPDRS motor subscale .15 .31 45
LED .04 .83 39
Depression .58** <.001 77
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Table 3
Spearman’s Correlations between Depression (BDI-II) and Participant- and Disease-related Variables in PD
VARIABLE rho p-value N
Age −.12 .29 77
Education −.22 .053 77
Disease Duration .03 .77 77
H&Y .22 .061 77
UPDRS total
.47** .001 45
UPDRS motor subscale .32 .03 45
LED −.03 .87 39
**p<0.01
PD=Parkinson’s Disease; BAI=Beck Anxiety Inventory; H&Y=Hoehn & Yahr; LED=Levodopa-equivalent dosage (available for 39/77 participants 
with PD); LPD=left-onset PD; RPD=right-onset PD; UPDRS=Unified Parkinson’s Disease Rating Scale (available for 45/77 participants with PD)
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Table 4
Spearman’s Correlations between Anxiety (BAI) and Neuropsychological Performance in PD
VARIABLE rho p-value N
TMT-B .37** .003 62
TMT B-A .34** .007 62
FAS −.14 .28 59
Animals −.24 .07 57
TMT-A .07 .61 62
Digit Span Forward .09 .50 58
Digit Span Backward −.19 .16 58
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Table 5
Spearman’s Correlations between Depression (BDI-II) and Neuropsychological Performance in PD
VARIABLE rho p-value N
TMT-B .21 .099 62
TMT B-A .18 .16 62
FAS −.08 .57 59
Animals −.25 .062 57
TMT-A .12 .34 62
Digit Span Forward −.03 .80 58
Digit Span Backward −.17 .21 58
**p<0.01
PD=Parkinson’s Disease; BAI=Beck Anxiety Inventory; FAS=phonemic fluency; Animals=categorical fluency.
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